Table 2. Multivariate analysis of acute and chronic GVHD, relapse, TRM, leukemia-free survival, and overall survival in adult ALL patients undergoing allogeneic HCT from 2000-2011.

	Acute GVHD	Chronic GVHD	Relapse	TRM	LFS	OS
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
8/8 URD vs RD	2.18 (1.76-2.70, p<0.0001)	1.28 (1.06-1.55, p=0.01)	0.77 (0.62-0.97, p=0.02)	1.16 (0.91-1.48, p=0.23)	0.95 (0.81-1.12, p=0.55)	1.01 (0.85-1.19, p=0.93)
7/8 URD vs RD	2.65 (2.06-3.42, p<0.0001)	1.46 (1.14-1.88, p=0.003)	0.75 (0.56-1.00, p=0.05)	1.92 (1.47-2.52, p<0.0001)	1.20 (0.98-1.46, p=0.07)	1.29 (1.05-1.58, p=0.01)
7/8 URD vs 8/8 URD	1.22 (1.00-1.48, p=0.05)	1.14 (0.91-1.44, p=0.24)	0.97 (0.74-1.28, p=0.84)	1.66 (1.32-2.08, p<0.0001)	1.26 (1.05-1.51, p=0.01)	1.28 (1.07-1.53, p=0.008)

Significant covariates in each of the final models: GVHD (use of ATG/alemtuzumab, donor/recipient sex matching, GVHD prophylaxis, graft type); Relapse (KPS, race, cytogenetics, conditioning regimen, disease status at transplant); TRM (age, KPS, race, GVHD prophylaxis, graft type, conditioning regimen); LFS (age, KPS, race, cytogenetics, GVHD prophylaxis, disease status at transplant, year of transplant); OS (age, KPS, race, cytogenetics, GVHD prophylaxis, disease status at transplant, graft type)